Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms

Obstetrics and Gynecology

Volumn 88, Issue 4, 1996, Pages 587-592

  Speroff, L ^a,b   Whitcomb, R W ^a,b   Kempfert, N J ^a,b   Boyd, R A ^a,b   Paulissen, J B ^a,b   Rowan, J P ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSE; MULTICENTER STUDY; PHARMACEUTICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SWEATING; TRANSDERMAL DRUG ADMINISTRATION; VASOMOTOR REFLEX;

EID: 0029791095     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1016/0029-7844(96)00272-4     Document Type: Article

References (9)

1. Steingold KA, Laufer L, Chetkowski RJ, De Fazio JD, Matt DW, Me Id rum DR, et al. Treatment of hot flushes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61: 627-632.
2. Adami S, Sippi R, Bertoldo F, Rossini M, Residori M, Maresca V, et al. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 1989;7: 79-86.
3. Ribot C, Tremollieres F, Pouilles JM, Lou vet P, Peyron R. Preventive effects of transdermal administration of 17β-estradiol on postmenopausal bone loss: A 2-year prospective study. Gynecol Endocrinol 1989;3: 259-268.
4. Powers MS, Schenkel L, Darlev PE, Good WR, Balestia JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β estradiol: Comparisons with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985;152: 1099-1106.
5. Boyd RA, Zegarac EA, Eldon MA, Sedman AJ, Forgue ST. Characterization of a 7-day 17β-estradiol transdermal delivery system: Pharmacokinetics in healthy postmenopausal women. Biopharm Drug Dispos (in press).
6. Draize H. Dermal toxicity. In: Appraisal of the safety of chemicals in foods, drugs, and cosmetics. Topeka, Kansas: The Association of Food and Drug Officials of the United States, 1965:45-59.
7. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore: Williams & Wilkins 1994:598.
8. Tagatz GE, Gurpide E. Hormone secretion by the normal human ovary. In: Creep RO, Astwood EB, eds. Handbook of physiology, section 7. Endocrinology. Vol. II: Female reproductive system. Washington DC: American Physiological Society, 1973:603-613.
9. Gordon SF. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol 1993; 1 73: 998-1004.